Designing First-In-Human Trials for Small Molecules and Biologics

Martha Donoghue, MD, in the Office of Oncologic Diseases at CDER, discusses key design considerations for first-in-human trials of oncology drugs including, defining patient populations for eligibility, selection of the appropriate starting dose, dose escalation design, minimizing patient risk, dose optimization, and initial assessment of antitumor activity.
Learn more at: www.fda.gov/drugs/news-events...
-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
Upcoming Training - www.fda.gov/cdersbia
SBIA Listserv - public.govdelivery.com/accoun...
SBIA 2021 Playlist - • 2021 CDER Small Busine...
SBIA LinkedIn: / cder-small-business-an...
SBIA Training Resources - www.fda.gov/cdersbialearn
Twitter - / fda_drug_info
Email - [e-mail]  
Phone - [phone] I [phone]